{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:26:32Z","timestamp":1773235592004,"version":"3.50.1"},"reference-count":27,"publisher":"Endocrinology Research Centre","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>This review examines the association between Parkinson\u2019s disease (PD) and diabetes, two global epidemics closely linked to aging. The analysis is based on recent epidemiological data indicating that diabetes significantly increases the risk of developing PD and exacerbates its progression, affecting both motor and cognitive functions. The paper explores shared pathophysiological mechanisms, including impaired insulin signaling, insulin resistance, oxidative stress, mitochondrial dysfunction, chronic inflammation and neuroinflammation, dysregulated glucose metabolism, and gut microbiota dysbiosis. These interconnected processes create a vicious cycle in which each pathology reinforces the others, driving neurodegeneration, particularly in vulnerable dopaminergic neurons of the substantia nigra. The uniqueness of this review lies in the integration of current research, providing a dual-perspective approach to comorbidity \u2014 addressing both neurodegenerative and metabolic dysfunctions. Understanding these shared mechanisms opens avenues for developing multi-targeted therapeutic strategies, including dietary interventions, lifestyle modifications, and gut microbiota modulation. This approach distinguishes the present review from similar works by offering a comprehensive perspective on the issue and emphasizing the need for further studies to identify precise biomarkers and develop effective disease-modifying treatments.<\/jats:p>","DOI":"10.14341\/probl13624","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:22:48Z","timestamp":1773163368000},"page":"48-55","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":0,"title":["The relationship between Parkinson\u2019s disease and metabolic disorders: the impact of systemic dysfunctions on neurodegeneration"],"prefix":"10.14341","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0632-6653","authenticated-orcid":true,"given":"F. A.","family":"Yusupov","sequence":"first","affiliation":[{"name":"Osh State University (OshSU)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5549-3832","authenticated-orcid":true,"given":"M. Sh.","family":"Abdykadyrov","sequence":"additional","affiliation":[{"name":"Osh State University (OshSU)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Labandeira CM, Fraga-Bau A, Arias Ron D, Alvarez-Rodriguez E, Vicente-Alba P, Lago-Garma J, Rodriguez-Perez AI. Parkinson\u2019s disease and diabetes mellitus: common mechanisms and treatment repurposing. Neural Regen Res. 2022;17(8):1652\u20131658. doi: https:\/\/doi.org\/10.4103\/1673-5374.332122","DOI":"10.4103\/1673-5374.332122"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Katunina EA, Zalyalova ZA, Pokhabov DV, Putyatin IA. Art and creativity in Parkinson\u2019s disease: the mysterious effects of dopamine. S.S. Korsakov J Neurol Psychiatry. 2025;125(4):13\u201320. (In Russ.). doi: https:\/\/doi.org\/10.17116\/jnevro202512504113","DOI":"10.17116\/jnevro202512504113"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Yusupov FA, Ydyrysov IT, Abdykadyrov MSh, Yusupova TF. Age and gender aspects of Parkinson\u2019s disease. Clin Med (Russ J). 2025;103(1):13\u201322. (In Russ.). doi: https:\/\/doi.org\/10.30629\/0023-2149-2025-103-1-13-22","DOI":"10.30629\/0023-2149-2025-103-1-13-22"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Dedov II, Shestakova MV, Mayorov AY, Shamkhalova MS, Sukhareva OYu, Galstyan GR et al. Diabetes mellitus type 2 in adults. Diabetes Mellitus. 2020;23(2S):4\u2013102. (In Russ.). doi: https:\/\/doi.org\/10.14341\/DM12507","DOI":"10.14341\/DM12507"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404:2077\u20132093. doi: https:\/\/doi.org\/10.1016\/S0140-6736(24)02317-1","DOI":"10.1016\/S0140-6736(24)02317-1"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Dedov II, Shestakova MV, Vikulova OK et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010\u20132022. Diabetes Mellitus. 2023;26(2):104\u2013123. (In Russ.). doi: https:\/\/doi.org\/10.14341\/DM13035","DOI":"10.14341\/DM13035"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Putilina MV. Potential of animal-derived neuropeptides in complex therapy of diabetic neuropathy in patients with type 2 diabetes mellitus. S.S. Korsakov J Neurol Psychiatry. 2025;125(4):83\u201387. (In Russ.). doi: https:\/\/doi.org\/10.17116\/jnevro202512504183","DOI":"10.17116\/jnevro202512504183"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Yusupov FA, Yuldashev AA, Ormonova GM, Abdykadyrov MSh. Disorders and pathologies of the peripheral nervous system. Bull Sci Pract. 2022;8(4):370\u2013384. (In Russ.). doi: https:\/\/doi.org\/10.33619\/2414-2948\/77\/41","DOI":"10.33619\/2414-2948\/77\/41"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Chen L, Wang C, Qin L, Zhang H. Parkinson\u2019s disease and glucose metabolism impairment. Transl Neurodegener. 2025;14(1):10. doi: https:\/\/doi.org\/10.1186\/s40035-025-00467-8","DOI":"10.1186\/s40035-025-00467-8"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Yu H, Sun T, He X, Wang Z, Zhao K, An J, Wen L, Li JY, Li W, Feng J. Association between Parkinson\u2019s Disease and Diabetes Mellitus: From Epidemiology, Pathophysiology and Prevention to Treatment. Aging Dis. 2022;13(6):1591\u20131605. doi: https:\/\/doi.org\/10.14336\/AD.2022.0325","DOI":"10.14336\/AD.2022.0325"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Sohail MU, Batool RM, Aamir J, Saad M, Aisha E, Jain H, Arshad MS, Ahmed R. Trends in Type 2 Diabetes Mellitus and Parkinson\u2019s Disease Related Mortality in the United States from 1999 to 2020. Diabetes Res Clin Pract. 2025;224:112239. doi: https:\/\/doi.org\/10.1016\/j.diabres.2025.112239","DOI":"10.1016\/j.diabres.2025.112239"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"K\u00f6nig A, Outeiro TF. Diabetes and Parkinson\u2019s Disease: Understanding Shared Molecular Mechanisms. J Parkinson\u2019s Dis. 2024;14(5):917\u2013924. doi: https:\/\/doi.org\/10.3233\/jpd-230104","DOI":"10.3233\/JPD-230104"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson\u2019s disease, insulin resistance and novel agents of neuroprotection. Brain. 2012;136(2):374\u2013384. doi: https:\/\/doi.org\/10.1093\/brain\/aws009","DOI":"10.1093\/brain\/aws009"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Stockmann O, Ye L, Greten S, Chemodanow D, Wegner F, Klietz M. Impact of diabetes mellitus type two on incidence and progression of Parkinson\u2019s disease: a systematic review of longitudinal patient cohorts. J Neural Transm. 2025;132(5):627\u2013635. doi: https:\/\/doi.org\/10.1007\/s00702-025-02882-7","DOI":"10.1007\/s00702-025-02882-7"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Tang H, Lu Y, Okun MS, Donahoo WT, Ramirez-Zamora A, et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson\u2019s Disease in Patients with Type 2 Diabetes: A PopulationBased Cohort Study. Mov Disord. 2024;39(11):1960\u20131970. doi: https:\/\/doi.org\/10.1002\/mds.29992","DOI":"10.1002\/mds.29992"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Berezutsky MA, Durnova NA, Kurchatova MN, Matvienko UA. Neurobiological potential of astragaloside IV and prospects for its use in the treatment of Alzheimer\u2019s disease. S.S. Korsakov J Neurol Psychiatry. 2025;125(2):7\u201312. (In Russ.). doi: https:\/\/doi.org\/10.17116\/jnevro20251250217","DOI":"10.17116\/jnevro20251250217"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Ahn B. Advances in Insulin Resistance\u2014Molecular Mechanisms, Therapeutic Targets, and Future Directions. Int J Mol Sci. 2025;26(6):2574. doi: https:\/\/doi.org\/10.3390\/ijms26062574","DOI":"10.3390\/ijms26062574"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Sergi D, Renaud J, Simola N, Martinoli MG. Diabetes, a contemporary risk for Parkinson\u2019s disease: Epidemiological and cellular evidence. Front Aging Neurosci. 2019;11:302. doi: https:\/\/doi.org\/10.3389\/fnagi.2019.00302","DOI":"10.3389\/fnagi.2019.00302"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Grubelnik V, Zmazek J, Markovi\u010d R, Gosak M, Marhl M. Mitochondrial dysfunction in pancreatic alpha and beta cells associated with type 2 diabetes mellitus. Life. 2020;10(12):348. doi: https:\/\/doi.org\/10.3390\/life10120348","DOI":"10.3390\/life10120348"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Dai C, Tan C, Zhao L, Liang Y, Liu G, Liu H, Zhong Y, Liu Z, Mo L, Liu X, Chen L. Glucose metabolism impairment in Parkinson\u2019s disease. Brain Res Bull. 2023;199:110672. doi: https:\/\/doi.org\/10.1016\/j.brainresbull.2023.110672","DOI":"10.1016\/j.brainresbull.2023.110672"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Ball N, Teo WP, Chandra S, Chapman J. Parkinson\u2019s disease and the environment. Front Neurol. 2019;10:218. doi: https:\/\/doi.org\/10.3389\/fneur.2019.00218","DOI":"10.3389\/fneur.2019.00218"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Cheng X, Wu T, Han L, Sun T, Huang G. Association between added sugars intake and Parkinson\u2019s disease status in U.S. adults: A crosssectional study from NHANES 1990\u20132020. Arch Public Health. 2024;82(1). doi: https:\/\/doi.org\/10.1186\/s13690-024-01445-8","DOI":"10.1186\/s13690-024-01445-8"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Sobral J, Empadinhas N, Esteves AR, Cardoso SM. Impact of nutrition on the gut microbiota: Implications for Parkinson\u2019s disease. Nutr Rev. 2025;83(4):713\u2013727. doi: https:\/\/doi.org\/10.1093\/nutrit\/nuae208","DOI":"10.1093\/nutrit\/nuae208"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Sujith Pavan, Prabhu AN, Gorthi SP, Shetty V, Rajesh V, Hegde A, Ballal M. Dietary interventions in Parkinson\u2019s disease: An update. Biomedicine. 2022;42(3):422\u2013426. doi: https:\/\/doi.org\/10.51248\/.v42i3.1639","DOI":"10.51248\/.v42i3.1639"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Su D, Cui Y, He C, Yin P, Bai R, Zhu J, Lam JS, Zhang J, Yan R, Zheng X, Wu J, Zhao D, Wang A, Zhou M, Feng T. Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ. 2025; e080952. doi: https:\/\/doi.org\/10.1136\/bmj-2024-080952","DOI":"10.1136\/bmj-2024-080952"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. Environmental risk factors and Parkinson\u2019s disease: A meta-analysis. Environ Res. 2001;86(2):122\u2013127. doi: https:\/\/doi.org\/10.1006\/enrs.2001.4264","DOI":"10.1006\/enrs.2001.4264"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Zeng J, Lo CH. Editorial: Lipid metabolism dysregulation in obesityrelated diseases and neurodegeneration. Front Endocrinol. 2025;16. doi: https:\/\/doi.org\/10.3389\/fendo.2025.1564003","DOI":"10.3389\/fendo.2025.1564003"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13624\/10963","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:23:01Z","timestamp":1773163381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,7]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13624","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"value":"2308-1430","type":"electronic"},{"value":"0375-9660","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,7]]}}}